Akèy › Lukemi lenfositè kwonik
Etid klinik pou Lukemi lenfositè kwonik ap rekrite nan Etazini
120 etid pou Lukemi lenfositè kwonik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
- Nashville, TN13 etid
- Jacksonville, FL11 etid
- Philadelphia, PA11 etid
- Atlanta, GA11 etid
- Dallas, TX10 etid
- Portland, OR10 etid
- Salt Lake City, UT10 etid
- Kansas City, MO10 etid
- San Diego, CA10 etid
- Pittsburgh, PA10 etid
- Denver, CO9 etid
- Charlotte, NC9 etid
- Miami, FL9 etid
- St. Louis, MO8 etid
- Los Angeles, CA8 etid
- Des Moines, IA8 etid
- Winston-Salem, NC8 etid
- Omaha, NE8 etid
- Queens, NY8 etid
- Tampa, FL8 etid
- Cleveland, OH8 etid
- Minneapolis, MN8 etid
- Clifton, NJ7 etid
- Cedar Rapids, IA7 etid
- Aurora, CO7 etid
- Mountain View, CA7 etid
- Fort Wayne, IN7 etid
- Detroit, MI7 etid
Pa eta
- Alabama7 etid
- Arizona15 etid
- Arkansas4 etid
- Colorado17 etid
- Connecticut4 etid
- Delaware4 etid
- Distrik Columbia4 etid
- Florid34 etid
- Georgia16 etid
- Idaho4 etid
- Illinois17 etid
- Indiana12 etid
- Iowa10 etid
- Kalifòni33 etid
- Kansas6 etid
- Kentucky7 etid
- Lwizyàn6 etid
- Main6 etid
- Maryland23 etid
- Massachusetts33 etid
- Michigan12 etid
- Minnesota29 etid
- Mississippi5 etid
- Missouri13 etid
- Montana7 etid
- Nebraska8 etid
- Nevada6 etid
- New Hampshire3 etid
- New Jersey13 etid
- New Mexico3 etid
- New York26 etid
- North Carolina34 etid
- Ohio43 etid
- Oklahoma4 etid
- Oregon16 etid
- Pennsylvania22 etid
- Rhode Island6 etid
- South Carolina5 etid
- South Dakota3 etid
- Tennessee17 etid
- Texas38 etid
- Utah10 etid
- Virginia12 etid
- Washington26 etid
- Wisconsin19 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Oct 2, 2026 · NCT05724121Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Ap rekriteFaz 3
Laj 65 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07321652Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06863402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07582432Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT03516617A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Ap rekriteFaz 2
Laj 75 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07685717A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06973187Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Sep 28, 2026 · NCT00923507Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 24, 2026 · NCT03986034A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06136559Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.